Beth Amiott, PHD

Alliance Director

Beth joined CARB-X as an Alliance Director for the diagnostics program in 2025, following 15 years in molecular in vitro diagnostics development at BioFire Diagnostics/bioMérieux. During her time at bioMérieux she directed laboratory teams (US and France) in collaborative studies and contributed scientific expertise and regulatory guidance for internal and partnership product development teams (assay, instrument, and software).  Successful product registrations (FDA, IVDD/IVDR, NMPA) included IVDs targeting multi-pathogen infectious disease challenges, including respiratory, bloodstream, gastrointestinal, CNS, and joint infections, medical countermeasures, antimicrobial resistance, and emerging pathogens.  Beth started in molecular assay and product development for human genetic identity testing at Promega Corporation before going back to academics to obtain her PhD in molecular biology from the University of Colorado (Anschutz Medical/Health Sciences campus) and conduct post-doctoral research at the University of Utah.